Otonomy to Present at Two Upcoming Investor Conferences
February 24 2015 - 8:00AM
Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of innovative therapeutics for diseases and
disorders of the inner and middle ear, today announced that David
A. Weber, Ph.D., president and chief executive officer, will
present at two upcoming investor conferences:
- Cowen & Company 35th Annual Health Care Conference, The
Boston Marriott Copley Place, Boston, March 4, 2015 at 10:40 a.m.
ET.
- 27th Annual Roth Conference, Ritz Carlton Laguna Niguel, March
11, 2015 at 12:00 p.m. PT.
A live audio webcast of each presentation will be available
through the Events and Presentations page of the company's
corporate website (www.otonomy.com).
About Otonomy
Otonomy is a clinical-stage biopharmaceutical company focused on
the development and commercialization of innovative therapeutics
for diseases and disorders of the ear. Otonomy's proprietary
technology provides sustained exposure of drugs to the middle and
inner ear following a single intratympanic injection. Otonomy has
three product candidates in development. AuriPro™ is an antibiotic
that has completed Phase 3 clinical trials in pediatric patients
with middle ear effusion at the time of tympanostomy tube placement
surgery. OTO-104 is a steroid that is in the first of two pivotal
clinical studies for the treatment of patients with Ménière's
disease. OTO-311 is an NMDA receptor antagonist in development as a
treatment for tinnitus. For additional information please visit
www.otonomy.com.
CONTACT: Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Vice President
619.849.5377
heidi@canalecomm.com
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Oct 2023 to Oct 2024